Journal of infection and public health · 2026
QIAreach® QuantiFERON-TB diagnostic performance to detect tuberculosis infection among people living with HIV in Brazil: A prospective study.
СтатьяОценочное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Spener-Gomes Renata, Costa Allyson G, Souza Alexandra B, Araújo-Pereira Mariana, Loiola Bruna P, Souza Eliza B, Carvalho Brenda K S, Marques Vitória C R, Cohn Silvia, Andrade Bruno B, Chaisson Lelia H, Golub Jonathan E, Cordeiro-Santos Marcelo
Аннотация
BACKGROUND: Identifying individuals with tuberculosis infection (TBI) at increased risk of progressing to active TB remains challenging. The World Health Organization recommends both the tuberculin skin test (TST) and the interferon-gamma release assay (IGRA), including QuantiFERON-TB Gold Plus (QFT®-Plus), for the detection of TBI. QIAreach®, a novel IGRA assay designed for resource-limited settings, has shown strong concordance with QFT®-Plus. However, data on immunosuppressed individuals are limited. To address this gap, we assessed the diagnostic performance of QIAreach® compared with QFT®-Plus in a high TB/HIV-burden setting.
METHODS: We prospectively evaluated QIAreach® at an HIV reference center in Manaus, Brazil. Blood samples from PLHIV aged ≥ 18 years with CD4 cell counts ≥ 350 cells/mm³ or with unavailable CD4 results at enrollment were tested using both assays per manufacturer instructions. Diagnostic performance (sensitivity, specificity, and predictive values) was assessed using QFT®-Plus as the reference standard. Cohen's kappa coefficient determined test agreement.
RESULTS: Among 266 participants (median age 37 years; 70% men; median CD4 537 cells/mm³), QIAreach® sensitivity, specificity, and negative predictive value (95% CI) were 0.97 (0.90-1.00), 0.73 (0.66-0.78), and 0.99 (0.96-0.99), respectively. Concordance (Cohen's kappa) was 0.36.
CONCLUSION: QIAreach® demonstrated high sensitivity and negative predictive value (NPV) in PLHIV. However, its increased false-positive rate affected specificity. Given its high NPV, further studies are needed to determine its role as a point-of-care triage test for TBI.
METHODS: We prospectively evaluated QIAreach® at an HIV reference center in Manaus, Brazil. Blood samples from PLHIV aged ≥ 18 years with CD4 cell counts ≥ 350 cells/mm³ or with unavailable CD4 results at enrollment were tested using both assays per manufacturer instructions. Diagnostic performance (sensitivity, specificity, and predictive values) was assessed using QFT®-Plus as the reference standard. Cohen's kappa coefficient determined test agreement.
RESULTS: Among 266 participants (median age 37 years; 70% men; median CD4 537 cells/mm³), QIAreach® sensitivity, specificity, and negative predictive value (95% CI) were 0.97 (0.90-1.00), 0.73 (0.66-0.78), and 0.99 (0.96-0.99), respectively. Concordance (Cohen's kappa) was 0.36.
CONCLUSION: QIAreach® demonstrated high sensitivity and negative predictive value (NPV) in PLHIV. However, its increased false-positive rate affected specificity. Given its high NPV, further studies are needed to determine its role as a point-of-care triage test for TBI.